Richard Pzena
Pzena Investment Management
Richard Pzena Biogen Inc stake
total: 584
Pzena Investment Management BIIB trades
- Total transactions:
- 21
- New positions:
- 5
- Sold out:
- 5
- Added:
- 7
- Reduced:
- 4
- Held since:
- 2023 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2023 Q3
According to 2026 Q2 report, Richard Pzena doesn't hold any Biogen Inc (BIIB) shares. To date, the estimated cost basis is nearly $284.85 for "buy" trades and estimated average "sell" price is $284.85. Pzena Investment Management first purchased BIIB in 2016 Q3, initially acquiring 642 shares. Richard Pzena later completely sold out the position and invested in Biogen Inc again in 2023 Q2. Since the initial investment in Biogen Inc (BIIB), Pzena Investment Management has made 20 more transactions.
When did Richard Pzena sell Biogen Inc (BIIB)?
Richard Pzena sold off the entire Biogen Inc (BIIB) position in 2023 Q3.
When did Richard Pzena buy Biogen Inc (BIIB)?
Richard Pzena first invested in Biogen Inc (BIIB) in 2016 Q3 at the reported quarter-end price of $313.08 per share.
What's the cost basis of Pzena Investment Management's BIIB stake?
The estimated cost basis for Biogen Inc (BIIB) stake is around $284.85 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $284.85
- Weighted AVG sell price:
- $284.85
Richard Pzena's historical trades in Biogen Inc
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$284.85
|
|
-100% (-1,618)
|
-0%
|
|
2023 Q2
|
0.00%
|
1,618
|
$284.85
|
$460,887
|
new
|
+0%
|
|
2022 Q4
|
0.00%
|
0
|
$267.20
|
|
-100% (-2,384)
|
-0%
|
|
2022 Q1
|
0.00%
|
2,384
|
$210.57
|
$502,000
|
new
|
+0%
|
|
2020 Q4
|
0.00%
|
$283.51
|
-100% (-2,857)
|
|||
|
2020 Q3
|
0.01%
|
$283.51
|
-11.90% (-386)
|
|||
|
2020 Q2
|
0.01%
|
$267.65
|
-93.12% (-43,908)
|
|||
|
2020 Q1
|
0.11%
|
$316.39
|
-5.07% (-2,519)
|
|||
|
2019 Q4
|
0.07%
|
$296.74
|
+1,455.59% (+46,477)
|
|||
|
2019 Q3
|
0.00%
|
$232.70
|
+37.75% (+875)
|
|||
|
2019 Q2
|
0.00%
|
$233.82
|
-5.43% (-133)
|
|||
|
2019 Q1
|
0.00%
|
$236.23
|
+16.38% (+345)
|
|||
|
2018 Q4
|
0.00%
|
$301.04
|
+12.98% (+242)
|
|||
|
2018 Q3
|
0.00%
|
$353.54
|
+4.13% (+74)
|
|||
|
2018 Q2
|
0.00%
|
$290.50
|
+2.46% (+43)
|
|||
|
2018 Q1
|
0.00%
|
$273.61
|
+87.65% (+816)
|
|||
|
2017 Q4
|
0.00%
|
$319.01
|
new
|
|||
|
2017 Q2
|
0.00%
|
$274.04
|
-100% (-759)
|
|||
|
2017 Q1
|
0.00%
|
$274.04
|
new
|
|||
|
2016 Q4
|
0.00%
|
$313.08
|
-100% (-642)
|
|||
|
2016 Q3
|
0.00%
|
$313.08
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.